Abraham Ceesay, Rapport Therapeutics CEO
Rapport bags $150M Series B just five months after nine-figure launch for epilepsy, psychiatry trials
Just five months after emerging with $100 million to test former Janssen neuroscience programs, Rapport Therapeutics is back with another nine-figure raise to take its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.